RxDoctor Payments Data

Jason Gutt, MD

Otolaryngology · Indianapolis, INNPI 1023175478

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 28.4% of the total.

$3,681in general payments, 2019–2025

Across 180 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$1K
  • GSK$764
  • Optinose US, Inc.$398
  • Sanofi$349
  • Aerin Medical Inc.$235
  • Acclarent, Inc$159
  • plus $731 from 21 others

What the payments were for

  • Food & beverage$3,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,681 in reported general payments places this provider in the 75th percentile of 193 otolaryngology providers in Indiana.

See all otolaryngology providers in Indiana

Medicare billing

Part B allowed, 2024
$115,056
Medicare patients
323
Services billed
1,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab17$62,457
XhanceFluticasone Propionate16$9,713
Epinephrine15$1,818
Ofloxacin54$1,717
Dexamethasone Sodium Phosphate14$918
Fluocinolone Acetonide Oil12$784
Omeprazole17$241
Fluticasone Propionate11$213
Methylprednisolone32$166
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$140
Cephalexin18$108
Ipratropium Bromide11$107
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid17$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$398$9,71316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 193 otolaryngology providers in Indiana.

Other otolaryngology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →